Results 151 to 160 of about 24,763,168 (195)

Gadolinium-Based Contrast Agent-Related Toxicities

CNS Drugs, 2018
In recent years, gadolinium-based contrast agents have been associated with different types of toxicity. In particular, nephrogenic systemic fibrosis, a progressive sclerotic-myxedematous systemic disease of unknown etiology, is related to gadolinium-based contrast agent administration in patients with kidney dysfunction.
Pasquini, Luca, Napolitano, Antonio, Visconti, Emiliano, Longo, Daniela, Romano, Andrea, Tomà, Paolo, Rossi Espagnet, Maria Camilla   +6 more
openaire   +4 more sources

The effect of gadolinium-based contrast agents on rat testis

Andrologia, 2018
Previous studies have reported that repeated administrations of linear gadolinium-based contrast agents lead to their accumulation in the brain and other tissues in individuals with normal renal functions. The purpose of this prospective animal study was to investigate the effect of multiple administrations of macrocyclic ionic (gadoteric acid) and ...
F. Beyazal Celiker, L. Tumkaya, T. Mercantepe, G. Turan, A. Yılmaz, M. Beyazal, A. Turan, M. F. Inecikli, M. Kösem   +8 more
openaire   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Alternatives to Gadolinium-Based Contrast Agents

Investigative Radiology, 2021
Abstract Gadolinium-based contrast agents have been used in hundreds of millions of patients in the past 30 years, with an exemplary safety record. However, assumptions made at their inception have been recently challenged, rekindling innovation efforts.
openaire   +2 more sources

Gadolinium-based contrast agents in children

Pediatric Radiology, 2018
Gadolinium-based contrast agents (GBCAs) are widely used in medical imaging, with greater than 300 million doses administered since their introduction. The risk of adverse reactions is very low, and GBCAs were thought to be very safe until the discovery of nephrogenic systemic fibrosis (NSF).
Michael N, Rozenfeld, Daniel J, Podberesky   +1 more
openaire   +2 more sources

Hypersensitivity reactions to gadolinium-based contrast agents

Current Opinion in Allergy & Clinical Immunology, 2017
Purpose of review Gadolinium-based contrast agents (GBCAs) have been utilized since the late 1980s to enhance the diagnostic value of MRI studies. They are known to have excellent safety profile and serious adverse reactions are uncommon despite widespread global use.
Jie Shen, Fok, William B, Smith
openaire   +2 more sources

Gadolinium-based Contrast Agent Biodistribution and Speciation in Rats

Radiology, 2023
Background Gadolinium retention has been observed in organs of patients with normal renal function; however, the biodistribution and speciation of residual gadolinium is not well understood. Purpose To compare the pharmacokinetics, distribution, and speciation of four gadolinium-based contrast agents (GBCAs) in healthy rats using MRI, mass spectrometry,
Mariane Le Fur, Brianna F. Moon, Iris Y. Zhou, Samantha Zygmont, Avery Boice, Nicholas J. Rotile, Ilknur Ay, Pamela Pantazopoulos, Adam S. Feldman, Ivy A. Rosales, Ira Doressa Anne L. How, David Izquierdo-Garcia, Lida P. Hariri, Andrei V. Astashkin, Brian P. Jackson, Peter Caravan   +15 more
openaire   +2 more sources

Gadolinium-Based Contrast: An Alternative Contrast Agent for Endovascular Interventions

Annals of Vascular Surgery, 2000
The radiocontrast substance gadoterate meglumine (Gd-DOTA) is used in magnetic resonance imaging. Because of its low rate of adverse drug reactions, we evaluated Gd-DOTA as an alternative contrast medium in diagnostic and therapeutic procedures. Twenty-three consecutive procedures were performed using undiluted contrast agent Gd-DOTA (376.9 mg/mL ...
J C, Parodi, L M, Ferreira
openaire   +2 more sources

Extracellular gadolinium-based contrast agents

Radiología (English Edition)
Extracellular gadolinium-based contrast agents (GBCA) are commonly used in magnetic resonance imaging (MRI) because they increase the detection of alterations, improve tissue characterisation and enable a more precise differential diagnosis. GBCAs are considered to be safe but they are not risk-free. When using GBCAs, it is important to be aware of the
R, Soler-Fernández, C, Méndez-Díaz, E, Rodríguez-García   +2 more
openaire   +2 more sources

Gadolinium Based Contrast Agents and NSF

Current Rheumatology Reviews, 2010
Gadolinium based contrast agents (GBCAs) have been linked to nephrogenic systemic fibrosis (NSF) in patients with severe renal dysfunction. This article reviews strategies to prevent this condition in patients at risk. These include administering only single dose GBCA, scheduling MRI for just before the next routine dialysis in dialysis patients ...
Honglei Zhang, Kevin Mennitt, Krishna Juluru, Martin R. Prince   +3 more
openaire   +1 more source